Skip to main content

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting · Phase 3 · NCT04965493

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

At a glance

Research payments reported, 2025
$6.1M
U.S. investigators named
57
Sites paid
45
Planned or actual enrollment
600

About the trial

Sponsor
Loxo Oncology, Inc. (with Eli Lilly and Company)
Tested
Pirtobrutinib (drug), Venetoclax (drug), Rituximab (drug)
Dates
Started 2021-09-20; completion 2027-10
Results posted
Not yet

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

From ClinicalTrials.gov, last updated 2026-01-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $6.1M in research payments for this study in 2025 (85 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.